British drugmaker AstraZeneca expects COVID vaccine result by year-end if trials resume

British drugmaker AstraZeneca expects COVID vaccine result by year-end if trials resume

The drugmaker said in a statement that the trials were paused "voluntarily", describing it as a "routine action" that will be investigated to ensure the "integrity of the trials" is maintained.

Brazil is the third hardest-hit country by COVID-19 after the USA and India, and has become a testing ground for at least two vaccine candidates.

Earlier, Serum Institute of India (SII), which has partnered with AstraZeneca for manufacturing the Oxford vaccine candidate, had announced that it is pausing clinical trials of the vaccine, and said that it is "reviewing the situation" and will keep the trials paused until AstraZeneca resumes them. And capacity is also in place for an Australian vaccine being developed at The University of Queensland to be available in large numbers by mid-2021.

Dr. Soumya Swaminathan, the World Health Organization's chief scientist, said the United Nations health agency wasn't overly concerned by the pause in the Oxford and AstraZeneca vaccine trial, describing it as "a wake-up call" to the global community about the inevitable ups and downs of medical research.

Serum Institute of India had paused clinical trials of a COVID-19 vaccine in the country this week.

Russian President Vladimir Putin said last month that the National Health Ministry has approved the vaccine and production will begin at two sites in Russia.

Nash Thrilled For Nets Coaching Opportunity
That doesn't necessarily mean he deserves to be a head coach, but he thinks his experience as a player holds weight. When Marks was looking for a coach this summer, Nash called and asked if this was the time for him to pursue it.

The vaccine, named after the world's first satellite launched by the Soviet Union in 1957, will still undergo large-scale testing or Phase 3 clinical trial to assess its safety and efficacy.

There is also a control group of other people who have had a vaccine but they do not know which one - the control group has in fact had a meningitis vaccine, Dr Smith said.

So the worst thing that could show up in any trials would be signs participants become more susceptible to the disease if they're immune to the Covid-19 spike protein because of a vaccine.

Britain's chief scientific adviser, Patrick Vallance, on Wednesday said similar events should be expected but progress on vaccines and therapeutics was positive overall. "And actually if it stopped it for one vaccine, it might stop it for all vaccines", he says. "But the phase 3 trials are still in progress, it's still early and we haven't heard any ongoing results from them yet".

Dr Smith said because the vaccine is potentially going to be administered to millions of people.

Related Articles